Acadia Healthcare Company Inc.

source: coverage-next-full ticker: ACAD company: Acadia Healthcare Company, Inc. step: 01 title: Business Overview & Model created: 2026-05-27

Step 01 — Business Overview: Acadia Healthcare Company, Inc. (ACAD)

1. Business Description

Acadia Healthcare Company, Inc. (NASDAQ: ACAD; SEC: ACHC) is the largest publicly traded pure-play behavioral health company in the United States. The company operates a network of 277 behavioral healthcare facilities across 40 states and Puerto Rico, providing treatment for psychiatric disorders, substance use disorders (SUDs), and co-occurring conditions. [S1]

The company's mission centers on providing high-acuity, complex-needs behavioral health care to patients who lack adequate access to quality mental health and addiction treatment services. Acadia differentiates through scale, geographic density, continuum-of-care offerings, and its network of comprehensive treatment centers (CTCs) for opioid use disorder (OUD). [S2]

2. Value-Chain Layer Map

PAYER LAYER (Medicaid 57.7% / Commercial 24.6% / Medicare 14.3% / Other 3.4%)
       ↓ Reimbursement flows
ACADIA HEALTHCARE (Operator Layer)
  ├── Facility acquisition / de novo development / joint ventures
  ├── Facility operations management (staffing, compliance, clinical)
  ├── Clinical programs (inpatient psychiatry, residential, MAT, PHP/IOP)
  └── Billing / revenue cycle management
       ↓ Services delivered
PATIENT LAYER (82,000+ patients served daily)
  ├── Acute psychiatric episodes (AIP facilities)
  ├── Residential treatment (longer-term)
  ├── Medication-assisted treatment (CTCs — opioids)
  └── Outpatient / PHP / IOP (step-down care)

3. Business Segments

Acadia does not formally report disaggregated segment revenue by service line in its XBRL. Based on 10-K and press release disclosures: [S1][S2]

Q1 2026: Acute inpatient psychiatric facility revenue = $470.7M (+14% YoY), illustrating the inpatient segment's dominant position. [S3]

4. Revenue Model

Core Revenue Equation: Revenue = (Patient Days) × (Revenue Per Patient Day) × (Facility Count)

• Patient Days: Volume metric; driven by facility capacity, occupancy rates, and payor referral flow
• Revenue Per Patient Day (RPD): Pricing metric; driven by payor mix, rate negotiations, and acuity of care
• Facility Count: Capacity metric; driven by de novo development, acquisitions, and closures

Q1 2026 same-facility revenue growth: +7.3% (1.6% patient days + 5.6% RPD) [S3] — demonstrates that the company currently grows primarily through pricing, not volume.

5. Payer Mix and Revenue Architecture [S2]

Medicaid dependency is the defining risk/characteristic of the business model. Medicaid rates are set by state programs; any state budget constraint can trigger rate cuts with direct margin impact. The company's 57.7% Medicaid concentration makes it highly sensitive to Medicaid policy.

6. Geographic Footprint

• States operated: 40 + Puerto Rico (Dec 2025) [S1]
• Facilities: 277 behavioral healthcare facilities [S1]
• Beds: 12,500+ [S1]
• CTC locations: 174 across 33 states [S2]
• Largest concentration: Southeast and Midwest, with presence in every major U.S. region

7. Growth Pathways (Five Strategic Vectors)

Per company disclosures, Acadia pursues five growth pathways: [S2]

1. Expansions of existing facilities (add beds/programs at existing sites)
2. Joint venture (JV) partnerships with health systems (shared ownership of new facilities)
3. De novo development (build new greenfield facilities; capital-intensive; 2-4 year startup losses)
4. Acquisitions (M&A of existing behavioral health operators)
5. Continuum expansion (adding service lines at existing facilities)

Current strategic posture (2025-2026): The company is pivoting away from aggressive de novo/acquisition growth toward organic optimization, cash flow generation, and debt reduction under activist/board pressure.

8. Recent Strategic Pivot

In September 2025, under activist and board pressure, Acadia announced: [S2][S4]

• CapEx reduction of ≥$300M in 2026 (from $572M in 2025 to $255-280M guided for 2026)
• Closure of 5 underperforming facilities
• Layoff of ~400 employees
• Pause on several growth projects
• Shift focus to FCF generation and same-facility performance improvement

This represents a significant strategic inflection from the growth-at-any-cost posture of 2022-2024.

Source Index

source: coverage-next-full ticker: ACAD company: Acadia Healthcare Company, Inc. step: 04 title: Financial Quality & Adversarial Research Sweep created: 2026-05-27

Step 04 — Financial Quality & Adversarial Research Sweep: ACAD

1. Statement Quality Adjustments

Income Statement Adjustments

Acadia's GAAP net income is distorted by several significant non-recurring or non-cash items. The following adjustments normalize the picture: [S1][S2]

Judgment [J]: FY2025 GAAP loss of $1.1B is primarily non-cash (goodwill impairment) and event-driven (securities settlement). The underlying business generated ~$609M Adj. EBITDA — roughly flat-to-growing from FY2024. The key question is whether legal charges normalize meaningfully below $135M/yr as investigations resolve.

Cash Flow Adjustments

Operating cash flow is understated relative to true operating performance due to large cash legal payments: [S1]

Note: Even adjusted, OCF is well below Adj. EBITDA (~$609M) due to working capital expansion (A/R growing as revenue scales), interest payments, and taxes.

Balance Sheet Quality

Goodwill: $1,296M (post-impairment) vs. $2,265M at FY2024 — the $996M write-down reflects management's acknowledgment that prior acquisition/de novo values were overstated. [S1]

Goodwill/Total Assets ratio: 23.5% (FY2025) — significant but manageable. Intangibles represent the cost of the company's growth-by-acquisition history.

Accounts Receivable: $440.6M — DSO ~49 days — normal for behavioral health where Medicaid/Medicare pay in 30-45 days but commercial claims can take longer. Allowance for doubtful accounts should be reviewed. [S1]

2. Adversarial Research Sweep

Short-Seller and Investigative Reports

No specific short-seller report identifying ACAD/ACHC as a primary target found in web research as of 2026-05-27. However, the DOJ/SEC investigation itself effectively serves as the "bear case" investigation:

Regulatory/Legal Actions [S3][S4]

Timeline of Legal/Regulatory Actions:

Assessment: The DOJ Criminal Division investigation is the dominant tail risk. Criminal behavioral health fraud prosecutions have resulted in settlements of $500M-$2B+ for large operators. If charges are brought, the company could face:

• Criminal fines
• Corporate integrity agreement (CIA) requiring costly compliance programs
• Potential exclusion from Medicare/Medicaid (extreme scenario — existential)

Probability assessment [J]: Medicare/Medicaid exclusion is very low probability given the company's scale (would harm patients); a CIA + civil settlement is more likely. Settlement magnitude is uncertain but $200-500M range is plausible given the scope of the investigation.

Operational Risk Indicators

Facility closure announcement (Oct 2025): Closing 5 underperforming facilities; laying off 400 employees. [S5]

• This is a positive signal (pruning bad assets) but also indicates the prior expansion was undisciplined
• Management acknowledged de novo startup losses have been higher than planned

Medicaid dependency and regulatory risk:

• NY Medicaid policy: $25-30M EBITDA headwind in 2026
• Federal Medicaid: DOGE-related federal budget discussions create policy uncertainty
• Pattern: State Medicaid rate changes are the most frequent source of earnings volatility for ACAD

Accounting Quality Flags

3. Financial Quality Summary

Overall Financial Quality: MEDIUM

The underlying revenue and Adj. EBITDA trajectory are solid — $3.3B revenue growing mid-single digits, ~18% Adj. EBITDA margin, strong operational scale. The quality concerns are:

1. Legal/regulatory overhang (DOJ Criminal + SEC) — binary tail risk
2. FCF deeply negative from CapEx cycle; normalization expected in 2026 but not yet demonstrated
3. Balance sheet leverage (4.1x net debt/Adj. EBITDA) limits financial flexibility
4. Management credibility damage from prior guidance misses and legal failings

Source Index